577 related articles for article (PubMed ID: 26118499)
1. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
2. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
3. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
5. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
Podar K; Pecherstorfer M
Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
[TBL] [Abstract][Full Text] [Related]
6. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
7. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic targets in multiple myeloma.
Cottini F; Anderson K
Clin Adv Hematol Oncol; 2015 Apr; 13(4):236-48. PubMed ID: 26352582
[TBL] [Abstract][Full Text] [Related]
9. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
10. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
11. New Insights in Anti-Angiogenesis in Multiple Myeloma.
Ribatti D; Vacca A
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
[TBL] [Abstract][Full Text] [Related]
12. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
Anreddy N; Hazlehurst LA
J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted therapies and combinations for the treatment of multiple myeloma.
Agarwal A; Mahadevan D
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H; Falank C; Avery L; Reagan MR
Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
[TBL] [Abstract][Full Text] [Related]
16. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
17. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC; Weber DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
[TBL] [Abstract][Full Text] [Related]
18. Novel targets and derived small molecule inhibitors in multiple myeloma.
Podar K
Curr Cancer Drug Targets; 2012 Sep; 12(7):797-813. PubMed ID: 22671928
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Features of Multiple Myeloma.
El Arfani C; De Veirman K; Maes K; De Bruyne E; Menu E
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662010
[TBL] [Abstract][Full Text] [Related]
20. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
Gooding S; Edwards CM
Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]